NASDAQ:RYTM - Rhythm Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.70 -0.85 (-4.14 %) (As of 01/20/2020 04:00 PM ET) Add Compare Today's Range$19.45Now: $19.70▼$20.7250-Day Range$19.70MA: $22.84▼$25.7952-Week Range$18.00Now: $19.70▼$31.94Volume343,265 shsAverage Volume210,009 shsMarket Capitalization$865.42 millionP/E RatioN/ADividend YieldN/ABeta0.66 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RYTM Previous Symbol CUSIPN/A CIK1649904 Webhttp://www.rhythmtx.com/ Phone857-264-4280Debt Debt-to-Equity Ratio0.02 Current Ratio6.78 Quick Ratio6.78Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.16 per share Price / Book2.75Profitability EPS (Most Recent Fiscal Year)($2.39) Net Income$-74,060,000.00 Net MarginsN/A Return on Equity-66.86% Return on Assets-60.23%Miscellaneous Employees54 Outstanding Shares43,930,000Market Cap$865.42 million Next Earnings Date3/13/2020 (Estimated) OptionableOptionable Receive RYTM News and Ratings via Email Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RYTM Rates by TradingView Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions What is Rhythm Pharmaceuticals' stock symbol? Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM." How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) announced its quarterly earnings results on Friday, November, 1st. The company reported ($1.04) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.06) by $0.02. View Rhythm Pharmaceuticals' Earnings History. When is Rhythm Pharmaceuticals' next earnings date? Rhythm Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Rhythm Pharmaceuticals. What price target have analysts set for RYTM? 6 brokerages have issued 12-month price objectives for Rhythm Pharmaceuticals' stock. Their forecasts range from $18.00 to $43.00. On average, they expect Rhythm Pharmaceuticals' stock price to reach $35.33 in the next year. This suggests a possible upside of 79.4% from the stock's current price. View Analyst Price Targets for Rhythm Pharmaceuticals. What is the consensus analysts' recommendation for Rhythm Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rhythm Pharmaceuticals. What are Wall Street analysts saying about Rhythm Pharmaceuticals stock? Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock: 1. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (1/9/2020) 2. LADENBURG THALM/SH SH analysts commented, "We’ve learned from management that the yield will be broken out by patient type. We continue to look for ~2,500 identified and diagnosed MC4R patients in the U.S., with roughly half of them being BBS patients (see Exhibit 4). While management has not provided its internal estimates, it has now stated the number of BBS/Alström patients has exceeded its expectations." (9/9/2019) 3. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and our $34 target price on RYTM shares after the company reported its 2Q19 financials and business update. As we highlighted in our recent upgrade note (here), at the current share price, we believe there is a favorable risk/reward ahead of the Phase 3 data readouts for setmelanotide in POMC and LEPR deficiency obesities which are expected in the coming weeks. We believe both Phase 3 studies will be positive and in our homerun" scenario the stock could move up to the low ~$40 range. Additionally, we believe the 4Q19 update from management on its ongoing patient identification efforts for POMC/LEPR and other MC4R pathway disorders remain an unappreciated catalyst investors should be tracking." (7/29/2019) Has Rhythm Pharmaceuticals been receiving favorable news coverage? Media coverage about RYTM stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rhythm Pharmaceuticals earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Rhythm Pharmaceuticals. Are investors shorting Rhythm Pharmaceuticals? Rhythm Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,960,000 shares, an increase of 15.6% from the December 15th total of 2,560,000 shares. Based on an average daily trading volume, of 289,600 shares, the short-interest ratio is currently 10.2 days. Currently, 11.8% of the company's stock are short sold. View Rhythm Pharmaceuticals' Current Options Chain. Who are some of Rhythm Pharmaceuticals' key competitors? Some companies that are related to Rhythm Pharmaceuticals include Myokardia (MYOK), PTC Therapeutics (PTCT), Taro Pharmaceutical Industries (TARO), Axsome Therapeutics (AXSM), Agios Pharmaceuticals (AGIO), Zai Lab (ZLAB), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Uniqure (QURE), Genmab A/S (GMAB), Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI) and Karuna Therapeutics (KRTX). What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Exelixis (EXEL), Nektar Therapeutics (NKTR), Amicus Therapeutics (FOLD), Intra-Cellular Therapies (ITCI), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Portola Pharmaceuticals (PTLA) and Dicerna Pharmaceuticals (DRNA). Who are Rhythm Pharmaceuticals' key executives? Rhythm Pharmaceuticals' management team includes the folowing people: Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)Mr. Hunter C. Smith, CFO & Treasurer (Age 50)Ms. Nithya Desikan, Chief Commercial Officer (Age 40)Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)Mr. Simon D. Kelner, Chief HR Officer (Age 46) When did Rhythm Pharmaceuticals IPO? (RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Rhythm Pharmaceuticals' stock price today? One share of RYTM stock can currently be purchased for approximately $19.70. How big of a company is Rhythm Pharmaceuticals? Rhythm Pharmaceuticals has a market capitalization of $865.42 million. The company earns $-74,060,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.View Additional Information About Rhythm Pharmaceuticals. What is Rhythm Pharmaceuticals' official website? The official website for Rhythm Pharmaceuticals is http://www.rhythmtx.com/. How can I contact Rhythm Pharmaceuticals? Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected] MarketBeat Community Rating for Rhythm Pharmaceuticals (NASDAQ RYTM)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 195 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 389MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2020 by MarketBeat.com StaffFeatured Article: Compound Annual Growth Rate (CAGR)
